MA54608A - Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer - Google Patents
Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancerInfo
- Publication number
- MA54608A MA54608A MA054608A MA54608A MA54608A MA 54608 A MA54608 A MA 54608A MA 054608 A MA054608 A MA 054608A MA 54608 A MA54608 A MA 54608A MA 54608 A MA54608 A MA 54608A
- Authority
- MA
- Morocco
- Prior art keywords
- heterobicyclic
- aza
- cancer
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862785519P | 2018-12-27 | 2018-12-27 | |
PCT/US2019/068652 WO2020139991A1 (fr) | 2018-12-27 | 2019-12-27 | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MA54608A true MA54608A (fr) | 2022-04-06 |
MA54608B1 MA54608B1 (fr) | 2023-02-28 |
Family
ID=69400625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA54608A MA54608B1 (fr) | 2018-12-27 | 2019-12-27 | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer |
Country Status (35)
Country | Link |
---|---|
US (1) | US20220144820A1 (fr) |
EP (1) | EP3902803B1 (fr) |
JP (2) | JP7418441B2 (fr) |
KR (1) | KR20220051301A (fr) |
CN (1) | CN113454085A (fr) |
AR (1) | AR117544A1 (fr) |
AU (1) | AU2019416349B2 (fr) |
BR (1) | BR112021012595A2 (fr) |
CA (1) | CA3124952A1 (fr) |
CL (1) | CL2021001721A1 (fr) |
CO (1) | CO2021009879A2 (fr) |
CR (1) | CR20210410A (fr) |
DK (1) | DK3902803T3 (fr) |
EA (1) | EA202191801A1 (fr) |
ES (1) | ES2942310T3 (fr) |
FI (1) | FI3902803T3 (fr) |
GE (1) | GEP20237519B (fr) |
HR (1) | HRP20230161T1 (fr) |
HU (1) | HUE061834T2 (fr) |
IL (1) | IL284326B1 (fr) |
JO (1) | JOP20210172A1 (fr) |
LT (1) | LT3902803T (fr) |
MA (1) | MA54608B1 (fr) |
MD (1) | MD3902803T2 (fr) |
MX (1) | MX2021007829A (fr) |
PE (1) | PE20212090A1 (fr) |
PL (1) | PL3902803T3 (fr) |
PT (1) | PT3902803T (fr) |
RS (1) | RS64135B1 (fr) |
SG (1) | SG11202106637SA (fr) |
SI (1) | SI3902803T1 (fr) |
TW (1) | TWI816962B (fr) |
UA (1) | UA127525C2 (fr) |
WO (1) | WO2020139991A1 (fr) |
ZA (1) | ZA202104423B (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA54452A (fr) | 2018-12-10 | 2022-03-16 | Ideaya Biosciences Inc | Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a |
WO2022026892A1 (fr) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Dérivés de pipéridin-1-yl-n-pyrydine-3-yl-2-oxo-acétamide utiles pour le traitement de cancers déficients en mtap et/ou accumulant mta |
CN115960098A (zh) * | 2020-09-11 | 2023-04-14 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
CN115141202A (zh) * | 2021-03-29 | 2022-10-04 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
CN117412967A (zh) * | 2021-06-02 | 2024-01-16 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a抑制剂 |
WO2023114507A1 (fr) * | 2021-12-17 | 2023-06-22 | Tango Therapeutics, Inc. | Forme cristalline de n-(6-amino-5-méthylpyridin-3-yl)-2-(benzo[d]thiazol-5-yl)-5-méthylpipéridin-1-yl)-2-oxoacétamide, compositions pharmaceutiques et leurs procédés d'utilisation |
WO2023116696A1 (fr) * | 2021-12-21 | 2023-06-29 | 南京正大天晴制药有限公司 | Inhibiteur hétérocyclique de la méthionine adénosyltransférase 2a |
WO2023169554A1 (fr) * | 2022-03-11 | 2023-09-14 | 赛诺哈勃药业(成都)有限公司 | Inhibiteur de méthionine adénosine transférase, son procédé de préparation et son utilisation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
AU2001292670A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2017319500C1 (en) * | 2016-08-31 | 2022-10-20 | Les Laboratoires Servier | Inhibitors of cellular metabolic processes |
AU2018274101C1 (en) | 2017-05-22 | 2022-09-15 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
MA52232A (fr) * | 2018-03-30 | 2021-02-17 | Agios Pharmaceuticals Inc | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer |
-
2019
- 2019-12-27 US US17/418,442 patent/US20220144820A1/en active Pending
- 2019-12-27 IL IL284326A patent/IL284326B1/en unknown
- 2019-12-27 BR BR112021012595-7A patent/BR112021012595A2/pt unknown
- 2019-12-27 AU AU2019416349A patent/AU2019416349B2/en active Active
- 2019-12-27 TW TW108148216A patent/TWI816962B/zh active
- 2019-12-27 EA EA202191801A patent/EA202191801A1/ru unknown
- 2019-12-27 FI FIEP19845796.2T patent/FI3902803T3/fi active
- 2019-12-27 HR HRP20230161TT patent/HRP20230161T1/hr unknown
- 2019-12-27 JP JP2021538127A patent/JP7418441B2/ja active Active
- 2019-12-27 EP EP19845796.2A patent/EP3902803B1/fr active Active
- 2019-12-27 SG SG11202106637SA patent/SG11202106637SA/en unknown
- 2019-12-27 ES ES19845796T patent/ES2942310T3/es active Active
- 2019-12-27 PL PL19845796.2T patent/PL3902803T3/pl unknown
- 2019-12-27 LT LTEPPCT/US2019/068652T patent/LT3902803T/lt unknown
- 2019-12-27 MX MX2021007829A patent/MX2021007829A/es unknown
- 2019-12-27 HU HUE19845796A patent/HUE061834T2/hu unknown
- 2019-12-27 MA MA54608A patent/MA54608B1/fr unknown
- 2019-12-27 DK DK19845796.2T patent/DK3902803T3/da active
- 2019-12-27 WO PCT/US2019/068652 patent/WO2020139991A1/fr active Application Filing
- 2019-12-27 CN CN201980092742.2A patent/CN113454085A/zh active Pending
- 2019-12-27 CA CA3124952A patent/CA3124952A1/fr active Pending
- 2019-12-27 RS RS20230240A patent/RS64135B1/sr unknown
- 2019-12-27 CR CR20210410A patent/CR20210410A/es unknown
- 2019-12-27 PE PE2021001086A patent/PE20212090A1/es unknown
- 2019-12-27 MD MDE20211082T patent/MD3902803T2/ro unknown
- 2019-12-27 GE GEAP201915703A patent/GEP20237519B/en unknown
- 2019-12-27 JO JOP/2021/0172A patent/JOP20210172A1/ar unknown
- 2019-12-27 SI SI201930515T patent/SI3902803T1/sl unknown
- 2019-12-27 KR KR1020217023828A patent/KR20220051301A/ko unknown
- 2019-12-27 PT PT198457962T patent/PT3902803T/pt unknown
- 2019-12-27 AR ARP190103903A patent/AR117544A1/es unknown
- 2019-12-27 UA UAA202104321A patent/UA127525C2/uk unknown
-
2021
- 2021-06-25 ZA ZA2021/04423A patent/ZA202104423B/en unknown
- 2021-06-25 CL CL2021001721A patent/CL2021001721A1/es unknown
- 2021-07-27 CO CONC2021/0009879A patent/CO2021009879A2/es unknown
-
2023
- 2023-12-11 JP JP2023208546A patent/JP2024015340A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA56050A (fr) | Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
MA52232A (fr) | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer | |
MA54609A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
MA54608A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
MA50082A (fr) | Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer | |
MA52780A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
MA52564A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
MA45798A (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
MA55136A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA50849A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
MA49069A (fr) | Procédés et compositions pour le traitement d'apnée du sommeil | |
MA47310A (fr) | Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer | |
MA51848A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52501A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52496A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA50417A (fr) | Procédés d'utilisation d'inhibiteurs de l'ehmt2 dans le traitement ou la prévention de troubles du sang | |
MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
MA53558A (fr) | Compositions et procédés pour le traitement d'infections virales | |
MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
MA52575A (fr) | Pansement pour le traitement de la peau endommagée | |
MA46836A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
MA51306A (fr) | Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase | |
MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie |